$ELOX
Eloxx Pharmaceuticals, Inc.

2022 Q4 Form 10-Q Financial Statement

#000095017022024490 Filed on November 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.731M $2.262M $5.035M
YoY Change -26.55% -55.07% 64.01%
% of Gross Profit
Research & Development $3.297M $4.880M $5.210M
YoY Change -58.33% -6.33% 53.24%
% of Gross Profit
Depreciation & Amortization $10.00K $23.00K $30.00K
YoY Change -64.29% -23.33% 87.5%
% of Gross Profit
Operating Expenses $6.028M $7.142M $10.25M
YoY Change -48.17% -30.29% 62.72%
Operating Profit -$7.142M -$10.25M
YoY Change -30.29% 62.72%
Interest Expense -$368.0K -$366.0K -$180.0K
YoY Change -20.0% 103.33% -43.75%
% of Operating Profit
Other Income/Expense, Net $77.00K -$366.0K $360.0K
YoY Change -201.67% -212.15%
Pretax Income -$6.319M -$7.508M -$9.885M
YoY Change -47.73% -24.05% 49.32%
Income Tax
% Of Pretax Income
Net Earnings -$6.319M -$7.508M -$9.885M
YoY Change -47.73% -24.05% 49.39%
Net Earnings / Revenue
Basic Earnings Per Share -$0.09 -$0.11
Diluted Earnings Per Share -$2.92 -$0.09 -$114.7K
COMMON SHARES
Basic Shares Outstanding 86.66M 86.66M 86.21M
Diluted Shares Outstanding 86.66M 86.21M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $19.20M $24.55M $52.43M
YoY Change -54.58% -53.17% 71.4%
Cash & Equivalents $19.20M $24.55M $52.43M
Short-Term Investments $0.00
Other Short-Term Assets $922.0K $1.117M $1.110M
YoY Change -23.93% 0.63% -31.48%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $20.13M $25.67M $53.54M
YoY Change -53.71% -52.05% 66.23%
LONG-TERM ASSETS
Property, Plant & Equipment $169.0K $215.0K $224.0K
YoY Change -21.76% -4.02% 50.34%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change -100.0%
Total Long-Term Assets $994.0K $1.208M $1.841M
YoY Change -40.08% -34.38% 151.5%
TOTAL ASSETS
Total Short-Term Assets $20.13M $25.67M $53.54M
Total Long-Term Assets $994.0K $1.208M $1.841M
Total Assets $21.12M $26.88M $55.38M
YoY Change -53.2% -51.47% 68.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.020M $1.595M $2.509M
YoY Change 119.0% -36.43% 293.26%
Accrued Expenses $2.799M $4.518M $2.611M
YoY Change -33.29% 73.04% -15.53%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $3.980M $2.530M $0.00
YoY Change -100.0%
Total Short-Term Liabilities $23.09M $21.68M $9.510M
YoY Change 131.95% 127.97% -4.8%
LONG-TERM LIABILITIES
Long-Term Debt $8.557M $9.863M $11.91M
YoY Change -28.67% -17.19% 52.26%
Other Long-Term Liabilities $135.0K $318.0K $964.0K
YoY Change -83.21% -67.01% 1506.67%
Total Long-Term Liabilities $8.557M $9.863M $11.91M
YoY Change -28.67% -17.19% 52.26%
TOTAL LIABILITIES
Total Short-Term Liabilities $23.09M $21.68M $9.510M
Total Long-Term Liabilities $8.557M $9.863M $11.91M
Total Liabilities $31.78M $31.86M $22.39M
YoY Change 39.67% 42.33% 25.31%
SHAREHOLDERS EQUITY
Retained Earnings -$274.4M -$268.1M -$226.2M
YoY Change 15.14% 18.52% 36.68%
Common Stock $263.7M $265.3M
YoY Change 0.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$10.66M -$4.982M $33.00M
YoY Change
Total Liabilities & Shareholders Equity $21.12M $26.88M $55.38M
YoY Change -53.2% -51.47% 68.12%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$6.319M -$7.508M -$9.885M
YoY Change -47.73% -24.05% 49.39%
Depreciation, Depletion And Amortization $10.00K $23.00K $30.00K
YoY Change -64.29% -23.33% 87.5%
Cash From Operating Activities -$5.661M -$6.946M -$7.588M
YoY Change -43.0% -8.46% 44.26%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$48.00K -$69.00K
YoY Change -100.0% -30.43%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00 -$48.00K -$69.00K
YoY Change -100.0% -30.43% -101.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 312.0K 1.500M 3.355M
YoY Change -295.0% -55.29% -368.4%
NET CHANGE
Cash From Operating Activities -5.661M -6.946M -7.588M
Cash From Investing Activities 0.000 -48.00K -69.00K
Cash From Financing Activities 312.0K 1.500M 3.355M
Net Change In Cash -5.349M -5.494M -4.302M
YoY Change -47.1% 27.71% -1892.5%
FREE CASH FLOW
Cash From Operating Activities -$5.661M -$6.946M -$7.588M
Capital Expenditures $0.00 -$48.00K -$69.00K
Free Cash Flow -$5.661M -$6.898M -$7.519M
YoY Change -42.88% -8.26%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Amendment Flag
AmendmentFlag
false
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001035354
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity File Number
EntityFileNumber
001-31326
dei Entity Registrant Name
EntityRegistrantName
ELOXX PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-1368850
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-1368850
dei Entity Address Address Line1
EntityAddressAddressLine1
480 Arsenal Way
dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
577-5300
dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value per share
dei Trading Symbol
TradingSymbol
ELOX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
86656221
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24554000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42268000
CY2022Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
263000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
299000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
854000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
913000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
25671000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
43480000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
215000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
216000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
993000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1443000
CY2022Q3 us-gaap Assets
Assets
26879000
CY2021Q4 us-gaap Assets
Assets
45139000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1595000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1379000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4518000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4196000
CY2022Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
2530000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2022Q3 us-gaap Due To Affiliate Current
DueToAffiliateCurrent
12223000
CY2021Q4 us-gaap Due To Affiliate Current
DueToAffiliateCurrent
3723000
CY2022Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
116000
CY2021Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
698000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
657000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
21680000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9955000
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9863000
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
11996000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
318000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
804000
CY2022Q3 us-gaap Liabilities
Liabilities
31861000
CY2021Q4 us-gaap Liabilities
Liabilities
22755000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
87077587
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
87071324
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
86656221
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
86649958
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
871000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
871000
CY2022Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
421366
CY2021Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
421366
CY2022Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
2190000
CY2021Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
2190000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
264406000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
262026000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-268069000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-238323000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-4982000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
22384000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
26879000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
45139000
CY2022Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
4880000
CY2021Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
5210000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
20430000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
14987000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2262000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5035000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7961000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16731000
CY2022Q3 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
CY2021Q3 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
22670000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
7142000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
10245000
us-gaap Operating Expenses
OperatingExpenses
28391000
us-gaap Operating Expenses
OperatingExpenses
54388000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7142000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10245000
us-gaap Operating Income Loss
OperatingIncomeLoss
-28391000
us-gaap Operating Income Loss
OperatingIncomeLoss
-54388000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-366000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
360000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1355000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-249000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7508000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-9885000
us-gaap Net Income Loss
NetIncomeLoss
-29746000
us-gaap Net Income Loss
NetIncomeLoss
-54637000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.85
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.85
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
86656221
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
86656221
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
86208754
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
86208754
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
86653811
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
86653811
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
64428187
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
64428187
us-gaap Profit Loss
ProfitLoss
-29746000
us-gaap Profit Loss
ProfitLoss
-54637000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
22670000
us-gaap Share Based Compensation
ShareBasedCompensation
2380000
us-gaap Share Based Compensation
ShareBasedCompensation
7567000
us-gaap Depreciation
Depreciation
67000
us-gaap Depreciation
Depreciation
86000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
450000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
672000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
397000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
298000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-84000
elox Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
116000
elox Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
0
elox Gain On Extinguishment Of Paycheck Protection Program Debt
GainOnExtinguishmentOfPaycheckProtectionProgramDebt
0
elox Gain On Extinguishment Of Paycheck Protection Program Debt
GainOnExtinguishmentOfPaycheckProtectionProgramDebt
808000
elox Loss On Extinguishment Of Term Debt
LossOnExtinguishmentOfTermDebt
0
elox Loss On Extinguishment Of Term Debt
LossOnExtinguishmentOfTermDebt
268000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-59000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-631000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
216000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
410000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
322000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-649000
us-gaap Payments For Merger Related Costs
PaymentsForMergerRelatedCosts
0
us-gaap Payments For Merger Related Costs
PaymentsForMergerRelatedCosts
1003000
elox Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-445000
elox Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-659000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26184000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25070000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
66000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
69000
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
2145000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-66000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2076000
elox Proceeds From Advances From Collaboration Partners
ProceedsFromAdvancesFromCollaborationPartners
8500000
elox Proceeds From Advances From Collaboration Partners
ProceedsFromAdvancesFromCollaborationPartners
2918000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
47718000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
11910000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
11383000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
238000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
23000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8500000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
50948000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-17750000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
27954000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
42567000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24724000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24817000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
52678000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24554000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
52432000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
263000
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
246000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24817000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
52678000
us-gaap Stock Issued1
StockIssued1
0
us-gaap Stock Issued1
StockIssued1
22335000
us-gaap Interest Paid Net
InterestPaidNet
968000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-4982000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
10230000
CY2021Q1 elox Restricted Stock Vested During Period Value
RestrictedStockVestedDuringPeriodValue
-94000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1308000
us-gaap Interest Paid Net
InterestPaidNet
415000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
22384000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
922000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-11620000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
11686000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
744000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-10618000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
1812000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
714000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7508000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-8694000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
2750000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6000
CY2021Q2 elox Restricted Stock Vested During Period Value
RestrictedStockVestedDuringPeriodValue
-143000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4035000
CY2021Q2 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
22335000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
47718000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-36058000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
40643000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
17000
CY2021Q3 elox Restricted Stock Vested During Period Value
RestrictedStockVestedDuringPeriodValue
-1000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2224000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-9885000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
32998000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-268100000
CY2022Q3 elox Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
138000
CY2021Q4 elox Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
413000
CY2022Q3 us-gaap Prepaid Insurance
PrepaidInsurance
391000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
123000
CY2022Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
325000
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
377000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
854000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
913000
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
386000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
387000
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
171000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
171000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
215000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
216000
CY2022Q3 us-gaap Depreciation
Depreciation
23000
CY2021Q3 us-gaap Depreciation
Depreciation
30000
us-gaap Depreciation
Depreciation
67000
us-gaap Depreciation
Depreciation
86000
CY2022Q3 elox Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
3577000
CY2021Q4 elox Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1849000
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
485000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1615000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
214000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
489000
CY2022Q3 elox Accrued Interest On Debt
AccruedInterestOnDebt
125000
CY2021Q4 elox Accrued Interest On Debt
AccruedInterestOnDebt
102000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
117000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
141000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4518000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4196000
us-gaap Debt Instrument Interest Rate Terms
DebtInstrumentInterestRateTerms
Outstanding principal on the loan accrued interest at a floating rate equal to the greater of (i) 5.25% per annum and (ii) the sum of 2.5% plus the prime rate, as published in the Wall Street Journal. Interest payments are payable monthly.
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
4204000
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
6101000
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
2195000
CY2022Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
12500000
CY2022Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
926000
CY2022Q3 us-gaap Long Term Debt
LongTermDebt
11574000
CY2022Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
2530000
CY2022Q3 elox Long Term Debt Maturities Final Fee Due
LongTermDebtMaturitiesFinalFeeDue
-819000
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9863000
elox Royalties Percentage Of Net Sales Based On Actual Amount Of Funding
RoyaltiesPercentageOfNetSalesBasedOnActualAmountOfFunding
0.06
CY2022Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
323892
CY2021Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
323892
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.31
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.31
elox Class Of Warrant Or Right Expiration Period
ClassOfWarrantOrRightExpirationPeriod
P0Y11M26D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8904444
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.24
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M23D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
254223
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3269497
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.46
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1685725
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
8.92
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10488216
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.16
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M20D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
16436
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3369835
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.80
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y5M1D
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
16436
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
714000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2224000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2380000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7567000
CY2022Q3 us-gaap Interest Expense Other
InterestExpenseOther
489000
CY2021Q3 us-gaap Interest Expense Other
InterestExpenseOther
224000
us-gaap Interest Expense Other
InterestExpenseOther
1368000
us-gaap Interest Expense Other
InterestExpenseOther
803000
CY2022Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
108000
CY2021Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
36000
us-gaap Interest And Other Income
InterestAndOtherIncome
133000
us-gaap Interest And Other Income
InterestAndOtherIncome
36000
CY2022Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2021Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-808000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-808000
CY2022Q3 elox Loss On Extinguishment Of Debt
LossOnExtinguishmentOfDebt
0
CY2021Q3 elox Loss On Extinguishment Of Debt
LossOnExtinguishmentOfDebt
268000
elox Loss On Extinguishment Of Debt
LossOnExtinguishmentOfDebt
0
elox Loss On Extinguishment Of Debt
LossOnExtinguishmentOfDebt
268000
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-35000
CY2021Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
8000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-4000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-22000
CY2022Q3 elox Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
-50000
CY2021Q3 elox Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
0
elox Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
116000
elox Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
0
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-366000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
360000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1355000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-249000
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
86208754
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
86653811
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7508000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-9885000
us-gaap Net Income Loss
NetIncomeLoss
-29746000
us-gaap Net Income Loss
NetIncomeLoss
-54637000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
86656221
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
86656221
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
86208754
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
86653811
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
64428187
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
64428187
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.85
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.85
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10812108
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9109440
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
between 1-for-2 and 1-for-40

Files In Submission

Name View Source Status
0000950170-22-024490-index-headers.html Edgar Link pending
0000950170-22-024490-index.html Edgar Link pending
0000950170-22-024490.txt Edgar Link pending
0000950170-22-024490-xbrl.zip Edgar Link pending
elox-20220930.htm Edgar Link pending
elox-20220930.xsd Edgar Link pending
elox-ex31_1.htm Edgar Link pending
elox-ex31_2.htm Edgar Link pending
elox-ex32_1.htm Edgar Link pending
elox-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
elox-20220930_cal.xml Edgar Link unprocessable
elox-20220930_def.xml Edgar Link unprocessable
elox-20220930_lab.xml Edgar Link unprocessable
elox-20220930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
elox-20220930_htm.xml Edgar Link completed
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending